A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis’ novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC).
Peter Ciszewski
Advertisement
Articles by Peter Ciszewski
Advertisement
Latest Updated Articles
Anti-Lung Cancer Compound ASA404 Progresses to Phase IIINovember 17th 2008
Advertisement
Advertisement
Trending on OncLive
1
First-Line Treatment Decisions in Metastatic Pancreatic Cancer: Setting the Stage
2
Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer
3
The OncFive: Top Oncology Articles for the Week of 6/14
4
Deeper Responses Linked to Improved Long-Term Outcomes With T-DXd/Pertuzumab in HER2+ Breast Cancer
5